Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Immuno-Oncology Congress 2022

GSK - The need to advance checkpoint blockade for cancer immunotherapy and the potential role of the CD226 Axis

Why is there a need to build on current immune checkpoint therapies?

Date

09 Dec 2022

Session

GSK - The need to advance checkpoint blockade for cancer immunotherapy and the potential role of the CD226 Axis

Topics

Fundamentals of Cancer Care Organisation

Tumour Site

Presenters

Solange Peters

Authors

S. Peters

Author affiliations

  • CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne/CH

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

What is the CD226 Axis?

Presenter: Solange Peters

Session: GSK - The need to advance checkpoint blockade for cancer immunotherapy and the potential role of the CD226 Axis

Resources:

Webcast

Panel discussion / Q&A

Presenter: Solange Peters

Session: GSK - The need to advance checkpoint blockade for cancer immunotherapy and the potential role of the CD226 Axis

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.